"Some cryogenic wart removers—which remove warts from the skin by freezing them off—have caught fire during use at home, harming consumers or setting fire to items around the house.
Since 2009, the Food and Drug Administratio"...
Targretin Gel Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Targretin (bexarotene) 1% Gel is a retinoid used to treat skin lesions of cutaneous T-cell lymphoma (CTCL) (Stage 1A and 1B) in patients who have not responded to or not tolerated other therapies. Common side effects include redness, itching, warmth, swelling, burning, scaling, or other irritation.
Targretin gel should be initially applied at a dosing frequency once every other day for the first week. The application frequency should be increased at weekly intervals to once daily, then twice daily, then three times daily and finally four times daily according to individual lesion tolerance. Targretin may interact with vitamin A supplements, insect repellents or other products that contain DEET, and other topical products used on the affected area at the same time. Tell your doctor all medications and supplements you use. Targretin gel must not be given to a pregnant woman or a woman who intends to become pregnant. It can harm a fetus. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Targretin (bexarotene) 1% Gel Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Patient Information in Detail?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
Targretin Gel in Detail - Patient Information: Side Effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using bexarotene topical and call your doctor at once if you have a serious side effect such as:
- severe skin irritation (pain, burning, stinging, itching) after applying this medication;
- severe skin rash or redness; or
- swelling, bleeding, or tearing of treated skin.
Less serious side effects may include:
- mild burning, stinging, or itching;
- mild pain, redness, or irritation; or
- skin dryness or peeling.
Read the entire detailed patient monograph for Targretin Gel (Bexarotene Gel)
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Targretin Gel FDA Prescribing Information: Side Effects
The safety of Targretin® gel has been assessed in clinical studies of 117 patients with CTCL who received Targretin® gel for up to 172 weeks. In the multicenter open-label study, 50 patients with CTCL received Targretin® gel for up to 98 weeks. The mean duration of therapy for these 50 patients was 199 days. The most common adverse events reported with an incidence at the application site of at least 10% in patients with CTCL were rash, pruritus, skin disorder, and pain.
Adverse events leading to dose reduction or study drug discontinuation in at least two patients were rash, contact dermatitis, and pruritus.
Of the 49 patients (98%) who experienced any adverse event, most experienced events categorized as mild (9 patients, 18%) or moderate (27 patients, 54%). There were 12 patients (24%) who experienced at least one moderately severe adverse event. The most common moderately severe events were rash (7 patients, 14%) and pruritus (3 patients, 6%). Only one patient (2%) experienced a severe adverse event (rash).
In the patients with CTCL receiving Targretin® gel, adverse events reported regardless of relationship to study drug at an incidence of 5% are presented in Table 1.
A similar safety profile for Targretin® gel was demonstrated in the Phase I-II program. For the 67 patients enrolled in the Phase I-II program, the mean duration of treatment was 436 days (range 12-1203 days). As in the multicenter study, the most common adverse events regardless of relationship to study drug in the Phase I-II program were rash (78%), pain (40%), and pruritus (40%).
Table 1: Incidence of All Adverse Events* and Application
Site Adverse Events with Incidence ≥ 5% for All Application Frequencies of
Targretin® Gel in the Multicenter CTCL Study
|COSTART 5 Body System/Preferred Term||All Adverse Events
N = 50
|Application Site Adverse Events
N = 50
|Skin and Appendages|
|Contact Dermatitis1||7 (14)||4 (8)|
|Exfoliative Dermatitis||3 (6)||0|
|Pruritus2||18 (36)||9 (18)|
|Rash3||36 (72)||28 (56)|
|Maculopapular Rash||3 (6)||0|
|Skin Disorder (NOS)4||13 (26)||9 (18)|
|Body as a Whole|
|Pain||15 (30)||9 (18)|
|Peripheral Edema||3 (6)||0|
|Hemic and Lymphatic|
|WBC Abnormal||3 (6)||0|
|Metabolic and Nutritional|
|Paresthesia||3 (6)||3 (6)|
|Cough Increased||3 (6)||0|
|* Regardless of association with treatment
Includes Investigator terms such as:
1 Contact dermatitis, irritant contact dermatitis, irritant dermatitis
2 Pruritus, itching, itching of lesion
3 Erythema, scaling, irritation, redness, rash, dermatitis
4 Skin inflammation, excoriation, sticky or tacky sensation of skin; NOS = Not Otherwise Specified
Read the entire FDA prescribing information for Targretin Gel (Bexarotene Gel)
Additional Targretin Gel Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.